Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07744139

Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis

The RaP-DMac-LiMe study (Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis) is a monocentric, non-profit observational study promoted by Fondazione Policlinico Universitario A. Gemelli IRCCS. Its primary aim is to identify immunological, genomic, and radiomic biomarkers associated with recurrence risk in patients with colorectal liver metastases (CRLM) undergoing curative-intent liver resection.

The study is based on the need to improve prognostic stratification in CRLM by integrating information from the tumor immune microenvironment, tumor genomics, radiomics, and clinical data. Particular attention is given to myeloid immune cells, especially dendritic cells and tumor-associated macrophages, whose role in metastatic progression and recurrence remains insufficiently understood.

The primary objective is to assess the association between myeloid immune profiles and recurrence risk through integrated molecular, spatial, genomic, and radiological analyses. Secondary objectives include characterizing the transcriptomic and genomic features of dendritic cells and macrophages, identifying radiomic and circulating tumor DNA (ctDNA) biomarkers, and evaluating their potential as non-invasive tools for recurrence prediction and patient stratification.

The study includes a retrospective cohort of approximately 160 patients treated between 2009 and 2023 and a prospective cohort of approximately 50 patients who will be followed for 24 months. Tumor tissue samples, peripheral blood, imaging data (CT/MRI), and clinical information collected during routine care will be analyzed without introducing any experimental interventions or deviations from standard clinical practice.

Analyses will include transcriptomic profiling, multiplex spatial characterization of immune cells, circulating tumor DNA sequencing using next-generation sequencing technologies, radiomic feature extraction, and integration of all data using statistical and machine learning approaches. Predictive models will be trained on retrospective data and independently validated in the prospective cohort.

The primary endpoint is the prediction of colorectal liver metastasis recurrence within two years after liver resection. Ultimately, the study aims to develop and validate a multimodal predictive model integrating immune, genomic, radiomic, and clinical variables to improve recurrence risk assessment and support personalized patient management.

The overall study duration is 36 months. All procedures will be conducted in accordance with ethical standards and data protection regulations, with samples and clinical data pseudonymized and handled in compliance with the GDPR.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years.
  • Histologically confirmed colorectal liver metastases.
  • Administration of neoadjuvant chemotherapy prior to liver resection, with objective tumour response classified as partial response (PR) or stable disease (SD) according to RECIST criteria.
  • Availability of a hepatobiliary contrast-enhanced MRI performed within 2 months before surgery.
  • Provision of informed consent for prospectively enrolled participants, or eligibility under Article 110-bis of the Italian Privacy Code for retrospectively enrolled participants.

Exclusion criteria

  • Recurrent metastatic disease.
  • Liver resection performed with non-curative intent.
  • Current or previous hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  • Concomitant malignancies or history of another malignancy treated within the previous 5 years.

Treatment and study plan

Radiogenomic and Immune Profiling

Other

Analysis of tumour tissue, radiological images, and clinical data collected during routine clinical care. Molecular, genomic, spatial, transcriptomic, and radiomic profiling will be performed to investigate associations with recurrence risk and clinical outcomes in patients with colorectal liver metastases. No investigational drugs, devices, or experimental procedures are administered as part of the study.

Prospective Radiogenomic and ctDNA Profiling

Other

Patients with histologically confirmed colorectal liver metastases undergoing standard clinical management and curative-intent liver resection, enrolled prospectively with collection of tumour tissue and peripheral blood samples. Prospective collection and analysis of tumour tissue, peripheral blood-derived ctDNA, radiological, genomic, immune and clinical data.

Primary outcomes

  1. Prediction of Colorectal Liver Metastasis Recurrence

    Time frame: 24 Months after liver resection

    Prediction of colorectal liver metastasis recurrence following curative-intent liver resection using an integrated model based on radiogenomic, immune, and clinical profiling. Recurrence will be assessed through routine clinical follow-up and radiological evaluation.

Secondary outcomes

  1. Correlation Between Myeloid Immune Cell Frequencies and Clinical Outcome Measures

    Time frame: Up to 24 Months after liver resection

    Correlation between dendritic cell and tumor-associated macrophage frequencies (% of CD45⁺ immune cells), measured by multiparametric flow cytometry, and overall survival (months), relapse-free survival (months), and recurrence status (yes/no).

  2. Genomic Alterations Associated With Immune Landscape Patterns

    Time frame: Baseline (analysis of collected tumour tissue and ctDNA samples)

    Identification of tumour-associated genetic alterations correlated with specific immune microenvironment profiles in colorectal liver metastases.

  3. Radiomic Features Associated With Immune Cell Distribution

    Time frame: Baseline (pre-operative MRI/CT imaging)

    Identification of radiomic features associated with the distribution and characteristics of dendritic cells and tumour-associated macrophages within tumour tissues.

  4. Performance of the Machine Learning-Based Recurrence Prediction Model

    Time frame: Up to 24 Months after liver resection

    Development and validation of a machine learning-based model for recurrence risk prediction. Model performance will be assessed using area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value, and negative predictive value.

Study contacts

Contact information is provided by the study sponsor or research team.

Simone Famularo, MD

CONTACT

[email protected]

+390630155626

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Acronym: RaP-DMac-LiMe

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Aug 4, 2026
Registry last updated
Aug 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.